Key Medical Takeaways
- 2010: ADA incorporated laboratory A1C of 6.5% or higher as a diagnostic criterion for diabetes.
- 2011: Annual standards continued integrating A1C-based diagnosis, prevention and individualized management.
- 2012: ADA/EASD published a major patient-centered position statement on treating hyperglycemia in type 2 diabetes.
- 2013: ADA standards continued emphasizing individualized treatment decisions and cardiovascular risk management.
- 2014: ADA recommendations explicitly described different A1C goals for selected patients, including less stringent goals when treatment risks outweighed benefits.
- These recommendations are presented for historical education and are not substitutes for current guidelines.
Quick Answer
Between 2010 and 2014, diabetes care became increasingly focused on combining reliable diagnosis with individualized treatment decisions.
In 2010, the American Diabetes Association formally included A1C ≥6.5% among the diagnostic criteria for diabetes, provided the test was performed using an appropriately standardized laboratory method.
In 2012, ADA and EASD published a joint position statement emphasizing that glucose-lowering treatment should consider each person's medical circumstances, preferences, hypoglycemia risk and treatment burden.
By 2014, ADA recommendations more explicitly described how glycemic goals could be more or less stringent depending on the individual patient.
ADA Diabetes Guidelines 2010–2014: Historical Timeline
These five years included several important developments in diagnosis, treatment decisions and the interpretation of glucose targets.
| Year | Major development | Clinical significance |
|---|---|---|
| 2010 | A1C diagnostic criterion | A standardized laboratory A1C of 6.5% or higher became an accepted ADA diagnostic criterion. |
| 2011 | Integrated diabetes care | Continued refinement of diagnosis, screening, monitoring, prevention and individual care plans. |
| 2012 | ADA/EASD patient-centered statement | Greater explicit attention to shared decisions and flexible glucose-lowering treatment strategies. |
| 2013 | Individualized goals | Continued emphasis on treatment risks, diabetes duration, cardiovascular health and comorbidities. |
| 2014 | More explicit target flexibility | Historical A1C goals below 7%, below 6.5% and below 8% were discussed for different patient circumstances. |
ADA Diabetes Guidelines 2010: A1C Becomes a Diagnostic Criterion
The 2010 ADA Standards marked a significant change in diabetes diagnosis.
Previously, diabetes diagnosis had relied mainly on plasma glucose measurements, including fasting plasma glucose and the oral glucose tolerance test.
The 2010 Standards added hemoglobin A1C of at least 6.5% as another accepted diagnostic criterion.
Historical diagnostic criteria in 2010
| Test | 2010 diagnostic threshold |
|---|---|
| A1C | ≥6.5%, standardized laboratory method |
| Fasting plasma glucose | ≥126 mg/dL (7.0 mmol/L) |
| 2-hour plasma glucose during a 75-g OGTT | ≥200 mg/dL (11.1 mmol/L) |
| Random plasma glucose | ≥200 mg/dL (11.1 mmol/L) with classic symptoms or hyperglycemic crisis |
In the absence of unequivocal hyperglycemia, an abnormal diagnostic result generally required confirmation.
The ADA specified that diagnostic A1C testing should use methods certified by the National Glycohemoglobin Standardization Program (NGSP) and standardized or traceable to the Diabetes Control and Complications Trial reference assay.
The 2010 document also cautioned that point-of-care A1C devices were not sufficiently accurate at that time for diagnostic use.
A1C became an additional diagnostic option that did not require fasting. However, A1C and glucose-based tests did not identify exactly the same individuals, so laboratory interpretation remained essential.
Original source: ADA Standards of Medical Care in Diabetes—2010.
ADA Diabetes Guidelines 2011: Diagnosis, Prevention and Long-Term Management
The 2011 ADA Standards continued integrating A1C-based diagnosis with existing glucose-based diagnostic methods.
The recommendations addressed:
- Diagnosis and classification of diabetes.
- Prediabetes and identification of individuals at elevated diabetes risk.
- Appropriate glucose monitoring.
- Individualized A1C targets.
- Medical nutrition therapy and exercise.
- Cardiovascular risk reduction.
- Kidney, eye, foot and neuropathy screening.
- Diabetes care in hospitals and other settings.
For many nonpregnant adults, an A1C goal below approximately 7% was considered reasonable, but more or less stringent goals could be appropriate in different circumstances.
The 2011 Standards also discussed continuous glucose monitoring as a useful adjunct for selected people with type 1 diabetes receiving intensive insulin therapy.
This was not the introduction of CGM itself. Rather, it reflected growing evidence concerning how the technology could be incorporated into clinical management.
Original source: ADA Standards of Medical Care in Diabetes—2011.
ADA Diabetes Guidelines 2012: The Patient-Centered Approach
In January 2012, ADA published its annual Standards of Medical Care in Diabetes.
Later in 2012, ADA and the European Association for the Study of Diabetes (EASD) published a separate position statement titled Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach.
This joint document became an important milestone in how treatment decisions were framed.
What did patient-centered diabetes care mean?
The 2012 statement emphasized that treatment should consider more than the glucose-lowering effectiveness of a medication.
Relevant factors included:
- Risk of hypoglycemia.
- Body weight and treatment-related weight changes.
- Age, diabetes duration and other medical conditions.
- Expected treatment benefits and possible adverse effects.
- Medication cost and access.
- Treatment complexity.
- Patient preferences and ability to follow the treatment plan.
Rather than relying on one fixed medication sequence for everyone, the approach encouraged decisions that reflected the person's circumstances.
Patient-centered diabetes care was not invented in 2012. The joint ADA/EASD publication gave this principle a particularly prominent role in the selection and intensification of glucose-lowering treatment.
Importantly, this ADA/EASD publication was a joint position statement, separate from the annual ADA Standards.
Original sources:
ADA Diabetes Guidelines 2013: Individualized Goals and Risk Management
The 2013 Standards continued emphasizing individualized diabetes treatment and management of cardiovascular risk.
Core areas included:
- Selection of appropriate A1C goals.
- Hypoglycemia prevention.
- Blood pressure and lipid management.
- Assessment of kidney function and albuminuria.
- Eye and foot screening.
- Diabetes education and self-management.
- Screening for type 2 diabetes in individuals at increased risk.
The guidance emphasized that a person's age, diabetes duration, coexisting illnesses and treatment safety could influence the choice of glycemic goals.
Diabetes screening in children and adolescents
The 2013 Standards also described risk-based screening for type 2 diabetes and prediabetes in selected children and adolescents with excess weight and additional risk factors.
This did not mean universal diabetes screening for every child. The recommendations specified risk criteria and appropriate ages for consideration.
Original source: ADA Standards of Medical Care in Diabetes—2013.
ADA Diabetes Guidelines 2014: More Explicit Individualization of A1C Targets
The 2014 Standards continued discussing A1C goals in terms of the individual's treatment benefits and risks.
For many nonpregnant adults, the general goal remained an A1C below 7%.
However, the Standards explicitly acknowledged situations where tighter or less stringent targets might be appropriate.
| Historical A1C target | Patient circumstances described in 2014 |
|---|---|
| Below 7% | A reasonable general goal for many nonpregnant adults. |
| Below 6.5% | Could be appropriate for selected patients when achievable without significant hypoglycemia or other adverse effects. |
| Below 8% | Could be appropriate in selected patients with severe hypoglycemia history, limited life expectancy, significant complications or extensive comorbidities. |
These thresholds are presented as examples from the 2014 historical standards, not individualized medical advice for current treatment.
Nutrition and cardiovascular health
The 2014 Standards also addressed medical nutrition therapy, including individualized eating patterns, carbohydrate quality and avoidance of excessive reliance on vitamin or herbal supplements without evidence of benefit.
Management remained broader than A1C and incorporated blood pressure, lipids and other cardiovascular risk factors.
A note about the 2014 publication
An erratum corrected certain glucose-unit conversions and gestational diabetes testing information in the original 2014 standards. When reviewing historical numerical thresholds, the corrected publication should be consulted rather than relying on uncorrected text.
Original documents:
A1C Diagnosis Versus A1C Monitoring: Why 2010 Matters
A1C was used for diabetes monitoring long before 2010.
The important historical change in 2010 was its formal acceptance as an additional diagnostic criterion by the ADA.
These two uses must be distinguished:
- Diagnostic A1C: Helps determine whether diabetes is present when performed and interpreted according to appropriate diagnostic standards.
- Monitoring A1C: Helps assess average glucose exposure over approximately the preceding two to three months in people with established diabetes.
A1C results can be affected by conditions that alter red blood cell survival or hemoglobin characteristics. Accordingly, even with the introduction of A1C diagnosis, glucose-based tests remained important.
For further patient education, see blood sugar levels by time of day.
How Individualized Diabetes Treatment Evolved
The 2010–2014 period illustrates an important shift in how clinicians interpreted diabetes evidence.
Glucose control remained important, but treatment decisions increasingly emphasized:
- Expected reduction in complications.
- Risk of treatment-induced hypoglycemia.
- Age and expected treatment horizon.
- Duration of diabetes.
- Cardiovascular and kidney health.
- Patient preferences and practical treatment burden.
Evidence from earlier cardiovascular outcome studies contributed to this approach, while the 2012 ADA/EASD statement formally emphasized patient-centered decision-making.
The lesson was not that glucose targets had become unimportant. Rather, targets needed to be interpreted in the context of the whole person.
How ADA Guidelines From 2010–2014 Compare With Modern Diabetes Care
Many foundations of diabetes management remain recognizable, including A1C assessment, patient education and prevention of complications.
However, the clinical environment changed significantly after 2014.
- Medication evidence: Later clinical trials established important cardiovascular and kidney outcomes for selected modern therapies.
- Continuous glucose monitoring: Sensor accuracy, integration with treatment and clinical applications expanded substantially.
- Insulin delivery: Automated insulin-delivery technologies became increasingly important.
- Obesity treatment: Additional medical options and evidence broadened therapeutic strategies.
- Risk reduction: Treatment decisions increasingly incorporated organ-protection evidence in addition to glucose reduction.
Historical medication sequences and glucose goals are useful for understanding how diabetes care evolved, but current decisions must consider newer evidence, available medications and each patient's clinical circumstances.
Frequently Asked Questions
What was the biggest ADA diabetes guideline change in 2010?
The ADA formally included A1C of 6.5% or higher as a diagnostic criterion for diabetes when measured using an appropriately standardized laboratory method.
Could diabetes still be diagnosed with fasting glucose in 2010?
Yes. A1C was added as another diagnostic option. Fasting plasma glucose, the oral glucose tolerance test and symptomatic random plasma glucose criteria remained part of diabetes diagnosis.
What did the 2012 ADA/EASD statement change?
It emphasized patient-centered treatment decisions, including medication effectiveness, hypoglycemia risk, weight, side effects, cost and patient preferences.
Were the 2012 ADA Standards and ADA/EASD statement the same document?
No. The ADA Standards were annual recommendations, while the ADA/EASD patient-centered statement was a separate joint publication later in 2012.
Did the ADA recommend A1C below 7% for everyone in 2014?
No. Below 7% was a general goal for many nonpregnant adults, but the Standards explicitly described circumstances where more or less stringent targets could be appropriate.
Was CGM available between 2010 and 2014?
Yes. CGM was already in use and discussed in ADA guidance for selected patients. However, available devices and their clinical applications differed considerably from modern systems.
Can 2010–2014 guidelines be used for current treatment?
They should be treated as historical sources. Current medical decisions require contemporary guidelines and an individualized clinical assessment.
Explore the ADA Diabetes Guidelines Cluster
Main guidelines hub
ADA and ADA/EASD Diabetes Guidelines Explained
Historical period: 2000–2004
ADA Diabetes Guidelines 2000–2004
Previous historical period: 2005–2009
ADA Diabetes Guidelines 2005–2009
Recent ADA/EASD guidance
ADA/EASD 2026 Diabetes Guidelines
Next historical article: ADA Diabetes Guidelines 2015–2019 — planned.
Medical References
- American Diabetes Association. Standards of Medical Care in Diabetes—2010. Diabetes Care. 2010;33(Suppl 1):S11–S61. Original ADA publication.
- American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S11–S61. Original ADA publication.
- American Diabetes Association. Standards of Medical Care in Diabetes—2012. Diabetes Care. 2012;35(Suppl 1):S11–S63. Original ADA publication.
- Inzucchi SE, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. ADA/EASD Position Statement. Diabetes Care. 2012;35:1364–1379. Joint position statement.
- American Diabetes Association. Standards of Medical Care in Diabetes—2013. Diabetes Care. 2013;36(Suppl 1):S11–S66. Original ADA publication.
- American Diabetes Association. Standards of Medical Care in Diabetes—2014. Diabetes Care. 2014;37(Suppl 1):S14–S80. Original ADA publication.
- American Diabetes Association. Erratum: Standards of Medical Care in Diabetes—2014 and Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2014;37:887. Published correction.
Medical information notice: This is an independently authored historical educational article and is not an official American Diabetes Association or EASD publication. It does not provide individualized medical advice. For diagnosis and treatment, consult current clinical recommendations and a qualified healthcare professional.